doi: 10.1097/AOG.0000000000004876.


Online ahead of print.

Affiliations

Item in Clipboard

Ann M Bruno et al.


Obstet Gynecol.


.

Abstract

After the global cesarean delivery rate nearly doubled between 2000 and 2015, cesarean deliveries now account for nearly one third of births in the United States. Although rates have plateaued, the high national cesarean delivery rate has garnered criticism from both lay and Academic communities because it has not been associated with improvements in maternal or neonatal outcomes. Efforts are underway to lower the cesarean delivery rate through implementation of hospital-level and national guidelines. However, the cesarean delivery rate that optimizes maternal and neonatal outcomes is not known. Defining a cesarean delivery rate that optimizes perinatal outcomes and reduces morbidity seems simple. However, there are a host of challenges to such a task, including determining the outcomes that are most meaningful to use, deciding the population that should define the rate, and incorporating person-centered decision making, given that people place different value on different outcomes. Rather than a “call” for cesarean delivery rate reductions of a specific and arbitrary magnitude, we need further attention to defining an evidence-based optimal target. This commentary summarizes current national and international cesarean delivery rate targets, discusses the challenges of identifying an evidence-based national cesarean delivery rate target, and explores future considerations for best defining a cesarean delivery rate target.

Conflict of interest statement

Financial Disclosure Torri D. Metz reports receiving UpToDate royalties for two topics on trial of labor after cesarean. Money was paid to her institution as a site PI for a preeclampsia point-of-care test. Her institution received money to conduct the study, which ended in August 2020. Money was paid to her institution from Pfizer—she was a site PI for a phase III respiratory syncytial virus vaccine trial. She is a member of the Pfizer Medical Advisory Board (January 15, 2021) and site PI for a COVID-19 vaccination trial in pregnancy. She has served on the Society for Maternal-Fetal Medicine Board of Directors. The other authors did not report any potential conflicts of interest.

References

    1. Boerma T, Ronsmans C, Melesse DY, Barros AJD, Barros FC, Juan L, et al. Global epidemiology of use of and disparities in caesarean sections. Lancet 2018;392:1341–8. doi: 10.1016/s0140-6736(18)31928-7



      DOI

    1. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: final data for 2017. Natl Vital Stat Rep 2018;67:1–50. doi: 10.1016/s0140-6736(18)31928-7



      DOI

    1. Gregory KD, Jackson S, Korst L, Fridman M. Cesarean versus vaginal delivery: whose risks? Whose benefits? Am J Perinatol 2012;29:7–18. doi: 10.1055/s-0031-1285829



      DOI

    1. Quiroz LH, Chang H, Blomquist JL, Okoh YK, Handa VL. Scheduled cesarean delivery: maternal and neonatal risks in primiparous women in a community hospital setting. Am J Perinatol 2009;26:271–7. doi: 10.1055/s-0028-1103155



      DOI

    1. Liu S, Liston RM, Joseph KS, Heaman M, Sauve R, Kramer MS. Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term. CMAJ 2007;176:455–60. doi: 10.1503/cmaj.060870



      DOI